Trial Profile

Safety, Tolerability and Efficacy and Dose Response of GLS-1027 in the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 15 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zenuzolac (Primary)
Indications COVID-19 pneumonia
Focus Adverse reactions; Therapeutic Use
Sponsors GeneOne Life Science

Most Recent Events

17 Jan 2025 Status changed from active, no longer recruiting to completed.
27 Aug 2024 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
11 Sep 2023 Planned End Date changed from 1 Jun 2023 to 1 Dec 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com